Announcement PDF +61 (03) 9482 3940 157 Heidelberg Rd, Northcote, VIC 3070 www.renerve.com.au until his retirement in February 2025. His focus in the role was solving complex challenges using innovative science Dr Savage joined the CSIRO, where he served as Science and Deputy Director of its Manufacturing Research Unit Western Australia. Pharma, Kuniko Limited and Indiana Resources. She holds BComm and LLB qualifications from The University of Ms McGuire currently serves as Non-Executive Chair of TechGen Metals and is a Non-Executive Director of LTR Association (Toronto). in corporate commercial, and banking and finance matters with Clayton Utz (Perth) and the Canadian Bankers and corporate management with particular expertise in legal and governance. Prior to this, she gained experience Secretary at US-based Anteris Technologies and Alexium International Group, building strong capability in strategy Before her career as a corporate advisor and board director, Ms McGuire was General Counsel and Company acquisitions, capital raisings and IPOs. focus on legal and governance matters, and has overseen corporate transactions including mergers and resources sectors, she has led strategy and corporate governance across a range of organisations, with a particular Company Secretary and in top-tier private legal practice. Specialising in the medical device, life sciences and companies experience by working as an advisor, Non-Executive Chair, Non-Executive Director, General Counsel, Ms McGuire brings over 15 years’ experience at both board and senior management level and extensive listed The board will assess the most appropriate chairperson moving forward and expects to formalise this shortly. 2025. of the Board renewal process announced at the Annual General Meeting and its announcement on 27 November It also announces the resignation of Mr Stephen Cooper and Dr Michael Panaccio, effective immediately, as part effective immediately. and Dr Paul Savage as Non-Executive Directors. Ms McGuire has also been appointed interim Chair products for peripheral nerve injury ("PNI") repair, is pleased to announce the appointments of Ms Maja McGuire ReNerve Limited (ASX, "ReNerve" or "the Company"), an Australian biotechnology company developing innovative • Resignation of Mr Stephen Cooper and Dr Michael Panaccio and leadership roles within the industry • Following a 35-year career with CSIRO, Dr Paul Savage brings outstanding experience across life sciences Counsel and Company Secretary • Maja McGuire brings more than 15 years’ experience as a Chair, Non-Executive Director, General ReNerve announces Board changes 4 December 2025 ASX Announcement 2 | P a g e and technology to help grow the Australian hi-tech manufacturing industry, particularly in the biomedical, engineered devices and advanced materials sectors. His responsibilities included maintaining organisational science excellence through future science initiatives, developing strategies to address challenges facing Australian industry, and leading talent acquisition and development, research and development risk and served on the board of several life science companies. Dr Savage’s scientific background is in biomedical science, particularly medicinal chemistry and drug discovery, biotherapeutics and medical devices. “We are delighted to welcome Maja and Paul to the ReNerve Board. Paul’s background in biomedical science and leadership in scientific innovation as well as global networks in the medical device and manufacturing, along with Maja’s extensive experience with listed companies, corporate strategy, governance and direct experience with medical device companies, will be instrumental as we look towards a transformational year for the Company and we continue grow our commercial business as well as progress our R&D and commercial development programs.” said CEO Dr Julian Chick. The appointments form part of ReNerve’s Board renewal process announced at the Company’s Annual General Meeting held on 27 November 2025. As part of this Board renewal process, both Stephen Cooper and Michael Panaccio have stepped down from the Board. “The board and management would like to thank Stephen and Michael who have been with the company from its inception as an early-stage research company, to one that has launched products into the US market and is starting to transform into a commercial medical device company. Stephen’s leadership as the Chair has been pivotal in the Company’s success to date and Michael’s insights and support have been essential to get us to this point today.” said Dr Chick. - ENDS - This announcement has been approved for release by the Company’s Board of Directors. For further information and enquiries, please contact: Dr Julian Chick CEO & Managing Director ReNerve Ltd +61 (03) 9482 3940 info@renerve.com.au Matthew Wright Investor & Media Relations NWR Communications +61 (0) 451 896 420 matt@nwrcommunications.com.au About ReNerve Limited (ASX:RNV) ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide. 3 | P a g e Proven Clinical Success ReNerve’s first flagship product, the FDA-cleared NervAlign® Nerve Cuff, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives. Comprehensive Product Portfolio ReNerve is advancing a complete suite of nerve repair solutions: • NervAlign® Nerve Cuff – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery. • Deep Dermal tissue product -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases. • Amniotic tissue product ranges -- Three amniotic tissue product ranges used to aid the healing of wounds. • NervAlign® Nerve Conduit Range – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends. • NervAlign® Nerve Guide Matrix – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting. • NervAlign® Bionic Nerve – Next-generation combination technology for the most challenging nerve repairs. Market Leadership and Growth With demonstrated market traction since the Company’s 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.1 Vision and Values We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery. 1 Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)